ERBB2 and breast cancer: Taken together, our findings suggest that elevated FAM83A expression is selected for in trastuzumab resistant HER2+ BC, including cells originating from trastuzumab-resistant HER2+ BC patients and cells selected for resistance by long term growth in trastuzumab.